2-三氟甲基-4-氨基嘧啶-5-醛 | 76574-50-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-三氟甲基-4-氨基嘧啶-5-醛
• 英文名称: 4-amino-2-trifluoromethylpyrimidine-5-carbaldehyde
• 英文别名: 4-Amino-2-(trifluoromethyl)pyrimidine-5-carbaldehyde
• CAS: 76574-50-0
• 化学式: C₆H₄F₃N₃O
• 分子量: 191.112
• InChiKey: CCUCOUJCNASVHL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  68.9
• 氢给体数：
  1
• 氢受体数：
  7

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  2,6-二氯苯乙腈 、 2-三氟甲基-4-氨基嘧啶-5-醛 在 sodium ethanolate 作用下， 以 乙醇 为溶剂， 反应 0.5h， 以29%的产率得到6-(2,6-Dichlorophenyl)-2-(trifluoromethyl)pyrido[2,3-d]pyrimidin-7-amine
  参考文献：
  名称：

  Antihypertensive activity of 6-arylpyrido[2,3-d]pyrimidin-7-amine derivatives

  摘要：

  A series of 51 6-arylpyrido[2,3-d]pyrimidin-7-amine derivatives was prepared and evaluated for antihypertensive activity in the conscious spontaneously hypertensive rat. A number of these compounds, notably 6-(2,6-dichlorophenyl)-2-methylpyrido[2,3-d]pyrimidin-7-amine (36), lowered blood pressure in these rats in a gradual and sustained manner to normotensive levels at oral doses of 10-50 mg/kg. Normalized blood pressure levels could then be maintained by single daily oral doses. The effect of structural variation in the 6-aryl group and in the 2 and 4 positions of the pyridopyrimidine ring on activity is reported and discussed.

  DOI：

  10.1021/jm00136a006
• 作为产物：
  描述：

  4-氨基-2-(三氟甲基)嘧啶-5-甲腈 在 镍 甲酸 、 氢气 作用下， 反应 3.0h， 生成 2-三氟甲基-4-氨基嘧啶-5-醛
  参考文献：
  名称：

  Antihypertensive activity of 6-arylpyrido[2,3-d]pyrimidin-7-amine derivatives

  摘要：

  A series of 51 6-arylpyrido[2,3-d]pyrimidin-7-amine derivatives was prepared and evaluated for antihypertensive activity in the conscious spontaneously hypertensive rat. A number of these compounds, notably 6-(2,6-dichlorophenyl)-2-methylpyrido[2,3-d]pyrimidin-7-amine (36), lowered blood pressure in these rats in a gradual and sustained manner to normotensive levels at oral doses of 10-50 mg/kg. Normalized blood pressure levels could then be maintained by single daily oral doses. The effect of structural variation in the 6-aryl group and in the 2 and 4 positions of the pyridopyrimidine ring on activity is reported and discussed.

  DOI：

  10.1021/jm00136a006

文献信息

• TW2016/5858
  申请人：——

  公开号：——

  公开（公告）日：——
• FUSED PYRAZOLE DERIVATIVE
  申请人：SUMITOMO DAINIPPON PHARMA CO., LTD.

  公开号：US20160318933A1

  公开（公告）日：2016-11-03

  The present invention provides a cyclic aminomethyl pyrimidine derivative including a pharmaceutically acceptable salt thereof with high selectivity for dopamine D 4 receptor, which is useful for treating a disease such as attention deficit hyperactivity disorder. Specifically, the present invention relates no a compound of formula (1) or a pharmaceutically acceptable salt thereof, wherein n and m are independently 1 or 2; W 1 , W 3 , and W 4 are independently single bond or optionally-substituted C 1-4 alkylene group; W 2 is optionally-substituted C 1-4 alkylene group; R 1 and R 2 are independently hydrogen atom, etc.; R 3 is hydrogen atom, halogen atom, etc.; X 1 and X 2 are independently single bond, oxygen atom, etc.; ring Q 1 is optionally-substituted 5- to 10-membered heteroaryl group, etc.; ring Q 2 is optionally-substituted 6-membered heteroaryl group, etc.
• Antihypertensive activity of 6-arylpyrido[2,3-d]pyrimidin-7-amine derivatives
  作者：Lawrence R. Bennett、C. John Blankley、Robert W. Fleming、Ronald D. Smith、Deirdre K. Tessman

  DOI：10.1021/jm00136a006

  日期：1981.4

  A series of 51 6-arylpyrido[2,3-d]pyrimidin-7-amine derivatives was prepared and evaluated for antihypertensive activity in the conscious spontaneously hypertensive rat. A number of these compounds, notably 6-(2,6-dichlorophenyl)-2-methylpyrido[2,3-d]pyrimidin-7-amine (36), lowered blood pressure in these rats in a gradual and sustained manner to normotensive levels at oral doses of 10-50 mg/kg. Normalized blood pressure levels could then be maintained by single daily oral doses. The effect of structural variation in the 6-aryl group and in the 2 and 4 positions of the pyridopyrimidine ring on activity is reported and discussed.